The global viral vector and plasmid DNA manufacturing market size is calculated at USD 8.66 billion in 2025 and is expected ...

Announcing a new article publication for Zoonoses journal. Vaccinia virus (VACV) confers cross-protective immunity against the variola virus, the causative agent of smallpox, and has therefore been ...

Viral vector vaccines use a version of a mild virus to safely deliver ... the ‘spike’ protein. This type of vaccine makes your immune system familiar with the spike protein, so it can kill the ...

As the industry moves towards a more integrated and diversified vaccine ecosystem, GeoVax’s MVA-based vaccines should provide a scalable, durable, and globally accessible solution that enhances the ...

How it works Convidencia is a viral vector vaccine using adenovirus five. With a viral vector, there is essentially a viral particle, which is programmed not to replicate. So, what is administered ...

Results of IMNN-101 Proof-of-Concept study demonstrate persistent immunogenicity in trial participants and further validate PlaCCine® ...

Announcing a new article publication for Zoonoses journal. Vaccinia virus (VACV) confers cross-protective immunity against variola virus, the causative agent of smallpox, and has therefore been ...

The Global Viral Vector Market was valued at approximately USD 3.10 billion in 2022 and is projected to grow at a robust CAGR of more than 11.5% during the forecast period 2023-2030. Read the Market ...

As viral vector technology matures and overcomes current challenges, it is expected to play an increasingly important role in advancing gene therapy, vaccine development, and biotechnology research, ...

Despite decades of efforts, tuberculosis remains a global health crisis, claiming over 1.3 million lives annually. In a comprehensive review published in Molecular Biomedicine , an international team ...